News stories about Catalent (NYSE:CTLT) have been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Catalent earned a news impact score of 0.13 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.1850793346204 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
- Catalent, Inc. to Present at Two Upcoming Investor Conferences (finance.yahoo.com)
- Zacks: Brokerages Expect Catalent Inc (CTLT) to Post $0.40 Earnings Per Share (americanbankingnews.com)
- Catalent Inc (CTLT) to Post Q3 2018 Earnings of $0.36 Per Share, William Blair Forecasts (americanbankingnews.com)
- Catalent Inc (CTLT) Receives Average Rating of “Buy” from Analysts (americanbankingnews.com)
A number of equities research analysts have issued reports on the stock. Royal Bank of Canada set a $48.00 price objective on shares of Catalent and gave the stock a “buy” rating in a research note on Monday, February 5th. Stephens downgraded shares of Catalent from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, February 6th. ValuEngine upgraded shares of Catalent from a “hold” rating to a “buy” rating in a research note on Wednesday, February 7th. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “buy” rating and set a $48.00 price target on the stock in a research note on Monday, November 6th. Finally, BidaskClub downgraded shares of Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Catalent presently has a consensus rating of “Buy” and a consensus target price of $45.60.
Catalent (NYSE:CTLT) last issued its quarterly earnings data on Monday, February 5th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. The business had revenue of $606.30 million during the quarter, compared to analyst estimates of $565.05 million. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The firm’s quarterly revenue was up 25.3% on a year-over-year basis. During the same quarter last year, the business earned $0.27 EPS. analysts predict that Catalent will post 1.53 EPS for the current year.
In other Catalent news, Director Uwe Roehrhoff acquired 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The stock was acquired at an average price of $39.22 per share, for a total transaction of $294,150.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total transaction of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Catalent (CTLT) Getting Somewhat Favorable News Coverage, Accern Reports” was posted by BBNS and is the property of of BBNS. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://baseballnewssource.com/markets/catalent-ctlt-getting-somewhat-favorable-news-coverage-accern-reports/1884831.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.